# CYP4F12

## Overview
CYP4F12 is a gene that encodes the protein cytochrome P450 family 4 subfamily F member 12, a member of the cytochrome P450 superfamily of enzymes. This protein is primarily involved in the oxidation of fatty acids and eicosanoids, playing a crucial role in the metabolism of both endogenous compounds and xenobiotics, including drugs. CYP4F12 is characterized by its enzymatic activity in the hydroxylation of arachidonic acid and prostaglandin H2 analogs, which are important for regulating inflammatory mediators (CAUFFIEZ2004Functional; Cauffiez2004Human). The protein is expressed in various tissues such as the liver, kidney, colon, heart, and small intestine, and is localized to the endoplasmic reticulum, where it contributes to specific metabolic pathways (Eksterowicz2014Characterization). Additionally, CYP4F12 has been implicated in interactions with viral proteins, such as the Hepatitis C virus nonstructural protein 5B, influencing viral replication (Zhu2016Inducible). The gene's expression and genetic variants have been associated with various clinical conditions, including cancer, highlighting its significance in disease prognosis and therapeutic responses (Li2021Genetic; Jia2023CYP4F12).

## Structure
The CYP4F12 protein is a member of the cytochrome P450 superfamily, characterized by its role in the oxidation of various substrates. The primary structure of CYP4F12 consists of 524 amino acids, resulting in a protein with a molecular weight of approximately 60 kDa (Cauffiez2004Human). The amino acid sequence of CYP4F12 shows 78-83% identity with other CYP4F enzymes, indicating a high degree of similarity within this subfamily (CAUFFIEZ2004Functional).

The secondary structure of CYP4F12 likely includes alpha-helices and beta-sheets, typical of cytochrome P450 enzymes, although specific details are not provided in the context. The tertiary structure involves the folding of these elements into a three-dimensional shape, which includes a heme-binding domain crucial for its enzymatic activity. This domain is essential for the enzyme's function in metabolizing substrates such as arachidonic acid and antihistaminic drugs (CAUFFIEZ2004Functional).

The quaternary structure of CYP4F12 is not detailed in the provided context, suggesting that it may function as a monomer, similar to other cytochrome P450 enzymes. The protein is expressed in various tissues, including the liver, kidney, colon, heart, and small intestine, indicating its involvement in diverse metabolic processes (Cauffiez2004Human).

## Function
CYP4F12 is a member of the cytochrome P450 superfamily, primarily involved in the oxidation of fatty acids and eicosanoids. It plays a significant role in the metabolism of both endogenous compounds and xenobiotics, including drugs. The enzyme is particularly active in the hydroxylation of arachidonic acid and prostaglandin H2 analogs, contributing to the regulation of inflammatory mediators (CAUFFIEZ2004Functional; Cauffiez2004Human). CYP4F12 is also involved in the metabolism of antihistaminic drugs such as ebastine and terfenadine, indicating its role in drug metabolism (Hashizume2002Involvement; Cauffiez2004Human).

In healthy human cells, CYP4F12 is expressed in various tissues, including the liver, kidney, colon, small intestine, and heart, with its activity localized to the endoplasmic reticulum (Eksterowicz2014Characterization). The enzyme's active site is characterized by increased steric constraints, which contribute to its decreased catalytic promiscuity compared to other P450 enzymes (Eksterowicz2014Characterization). This structural feature allows CYP4F12 to selectively catalyze specific metabolic pathways, impacting both the detoxification processes and the regulation of inflammatory responses in the body (Eksterowicz2014Characterization).

## Clinical Significance
Mutations and alterations in the CYP4F12 gene have been associated with various diseases and conditions. In glioma, a common and fatal primary malignant tumor of the central nervous system, a novel genome-wide significant locus, rs688755, in the CYP4F12 gene has been identified. This single nucleotide polymorphism (SNP) is associated with an increased risk of glioma, suggesting that genetic variants in CYP4F12 may contribute to glioma susceptibility (Li2021Genetic).

In head and neck squamous cell carcinoma (HNSC), CYP4F12 expression levels are linked to patient prognosis. High expression of CYP4F12 is associated with better overall survival and disease-free survival rates. Conversely, low expression correlates with poor survival outcomes and reduced efficacy of immune checkpoint blockade therapy. CYP4F12 expression is also related to immune cell infiltration, particularly B cells and CD4+ T cells, indicating its role in modulating immune responses in HNSC (Jia2023CYP4F12).

In hepatocellular carcinoma (HCC), CYP4F12 mRNA levels are negatively correlated with cell-cycle-associated genes, suggesting a potential role as a favorable prognostic factor (Jarrar2019Molecular). These findings highlight the clinical significance of CYP4F12 in cancer prognosis and therapy response.

## Interactions
CYP4F12 interacts with the Hepatitis C virus (HCV) nonstructural protein 5B (NS5B), an RNA-dependent RNA polymerase crucial for HCV replication. This interaction was confirmed using a yeast two-hybrid assay, demonstrating that CYP4F12 physically associates with NS5B, enhancing the efficiency of RNA synthesis by NS5B and promoting HCV replication (Zhu2016Inducible). The study also found that overexpression of CYP4F12 facilitates HCV replication, while knockdown of CYP4F12 decreases HCV replication and viral protein expression (Zhu2016Inducible).

The transcriptional regulation of CYP4F12 involves interactions with transcription factors such as SREBP1 and p50, which bind to specific regions of the CYP4F12 promoter. These factors have a competitive binding relationship, affecting the transcriptional regulation of CYP4F12 (Zhu2016Inducible). The critical region in the CYP4F12 promoter for activation by HCV proteins was identified as the fragment -262∼+154, containing binding sites for p50 and SREBP1. Mutations in these binding sites significantly impact the activation of CYP4F12 expression, highlighting their importance in the interaction between CYP4F12 and HCV proteins (Zhu2016Inducible).


## References


[1. (CAUFFIEZ2004Functional) C CAUFFIEZ. Functional characterization of genetic polymorphisms identified in the human cytochrome p450 4f12 (cyp4f12) promoter region. Biochemical Pharmacology, 67(12):2231–2238, June 2004. URL: http://dx.doi.org/10.1016/s0006-2952(04)00158-3, doi:10.1016/s0006-2952(04)00158-3. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0006-2952(04)00158-3)

[2. (Cauffiez2004Human) Christelle Cauffiez, Florian Klinzig, Emmanuel Rat, Gilles Tournel, Delphine Allorge, Dany Chevalier, Nicolas Pottier, Tonio Lovecchio, Jean-Frédéric Colombel, Michel Lhermitte, Jean-Marc Lo-Guidice, and Franck Broly. Human cyp4f12 genetic polymorphism: identification and functional characterization of seven variant allozymes. Biochemical Pharmacology, 68(12):2417–2425, December 2004. URL: http://dx.doi.org/10.1016/j.bcp.2004.08.025, doi:10.1016/j.bcp.2004.08.025. This article has 10 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/j.bcp.2004.08.025)

[3. (Hashizume2002Involvement) Takanori Hashizume, Susumu Imaoka, Masashi Mise, Yoshiaki Terauchi, Toshihiko Fujii, Hisashi Miyazaki, Tetsuya Kamataki, and Yoshihiko Funae. Involvement of cyp2j2 and cyp4f12 in the metabolism of ebastine in human intestinal microsomes. Journal of Pharmacology and Experimental Therapeutics, 300(1):298–304, January 2002. URL: http://dx.doi.org/10.1124/JPET.300.1.298, doi:10.1124/jpet.300.1.298. This article has 211 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/JPET.300.1.298)

[4. (Eksterowicz2014Characterization) John Eksterowicz, Dan A. Rock, Brooke M. Rock, Larry C. Wienkers, and Robert S. Foti. Characterization of the active site properties of cyp4f12. Drug Metabolism and Disposition, 42(10):1698–1707, July 2014. URL: http://dx.doi.org/10.1124/dmd.114.059626, doi:10.1124/dmd.114.059626. This article has 15 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1124/dmd.114.059626)

[5. (Li2021Genetic) Nan Li, Hangyu Shi, Pengfei Hou, Lu Gao, Yongqiang Shi, Weiyang Mi, Gang Zhang, Ning Wang, Wei Dai, Lin Wei, Tianbo Jin, Yongzhi Shi, and Shiwen Guo. Genetic variants of <scp>cyp4f12</scp> gene are associated with glioma susceptibility. International Journal of Cancer, 149(11):1910–1915, August 2021. URL: http://dx.doi.org/10.1002/ijc.33755, doi:10.1002/ijc.33755. This article has 5 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.33755)

[6. (Jia2023CYP4F12) Wenming Jia, Shuai Chen, Ran Wei, Xiaoqi Yang, Minfa Zhang, Ye Qian, Heng Liu, and Dapeng Lei. Cyp4f12 is a potential biomarker and inhibits cell migration of head and neck squamous cell carcinoma via emt pathway. Scientific Reports, July 2023. URL: http://dx.doi.org/10.1038/s41598-023-37950-z, doi:10.1038/s41598-023-37950-z. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-023-37950-z)

[7. (Jarrar2019Molecular) Yazun Bashir Jarrar and Su-Jun Lee. Molecular functionality of cytochrome p450 4 (cyp4) genetic polymorphisms and their clinical implications. International Journal of Molecular Sciences, 20(17):4274, August 2019. URL: http://dx.doi.org/10.3390/ijms20174274, doi:10.3390/ijms20174274. This article has 48 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/ijms20174274)

[8. (Zhu2016Inducible) Sheng-Li Zhu, Li Wang, Zhong-Ying Cao, Jun Wang, Ming-Zhen Jing, Zhang-Chuan Xia, Fang Ao, Lin-Bai Ye, Shi Liu, and Ying Zhu. Inducible cyp4f12 enhances hepatitis c virus infection via association with viral nonstructural protein 5b. Biochemical and Biophysical Research Communications, 471(1):95–102, February 2016. URL: http://dx.doi.org/10.1016/j.bbrc.2016.01.173, doi:10.1016/j.bbrc.2016.01.173. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.bbrc.2016.01.173)